Growth parameters, metastasis occurrence, and drug response of HBC xenografts
| Growth parameters | Drug response | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor xenograft code | Doubling time* (days) | Lung metastasis positive/total nb (%) | Treatments | Tumor growth inhibition† (%) | T/C Growth delay index‡ | Complete response (%) | Responder§ | ||||||
| HBCx-1 | 15 | 1/6 | AC | 90 | No regrowth | 100 | High R | ||||||
| Docetaxel | 61 | 2 | 0 | R | |||||||||
| HBCx-2 | 10 | 1/15 (7%) | AC | 18 | 1.2 | 0 | No | ||||||
| Docetaxel | 18 | 1.1 | 0 | No | |||||||||
| HBCx-3 | 8 | 0/20 (0%) | AC | 46 | 1.6 | 0 | No | ||||||
| Docetaxel | 40 | 1.6 | 0 | No | |||||||||
| Degarelix | 60 | 2.4 | 0 | R | |||||||||
| HBCx-4 | 10 | 0/11 (0%) | AC | 50 | 1.6 | 0 | No | ||||||
| Docetaxel | 1 | 1 | 0 | No | |||||||||
| HBCx-5 | 8 | 15/17 (88%) | AC | 90 | No regrowth | 0 | R | ||||||
| Docetaxel | 78 | No regrowth | 0 | R | |||||||||
| Trastuzumab | 47 | 1.1 | 0 | No | |||||||||
| HBCx-6 | 14 | 0/2 | AC | 100 | No regrowth | 100 | High R | ||||||
| Docetaxel | 11 | 1.1 | 0 | No | |||||||||
| HBCx-7 | 9 | 0/9 (0%) | AC | 47 | 1.4 | 0 | Low R | ||||||
| Docetaxel | 87 | No regrowth | 25 | R | |||||||||
| HBCx-8 | 5 | 3/29 (10%) | AC | 100 | No regrowth | 100 | High R | ||||||
| Docetaxel | 42 | 1.6 | 0 | Low R | |||||||||
| HBCx-9 | 5 | 0/23 (0%) | AC | 68 | No regrowth | 0 | R | ||||||
| Docetaxel | 100 | No regrowth | 25 | R | |||||||||
| HBCx-10 | 17 | 1/19 (5%) | AC | 100 | No regrowth | 100 | High R | ||||||
| Docetaxel | 48 | 1.1 | 0 | No | |||||||||
| HBCx-11 | 14 | 1/4 | AC | 85 | No regrowth | 0 | R | ||||||
| Docetaxel | 48 | 1.7 | 0 | Low R | |||||||||
| HBCx-13 | 13 | 3/14 (21%) | AC | 100 | No regrowth | 100 | High R | ||||||
| Docetaxel | 46 | 1.05 | 0 | No | |||||||||
| Trastuzumab | 95 | No regrowth | 100 | High R | |||||||||
| HBCx-14 | 10 | 7/8 (88%) | AC | 80 | No regrowth | 0 | R | ||||||
| Docetaxel | 23 | 1.7 | 0 | No | |||||||||
| HBCx-15 | 4 | 0/23 (0%) | AC | 99 | No regrowth | 100 | R | ||||||
| Docetaxel | 42 | 1.4 | 0 | No | |||||||||
| HBCx-12 | 7 | 16/16 (100%) | AC | 52 | 2 | 0 | R | ||||||
| Docetaxel | 28 | 1 | 0 | No | |||||||||
| HBCx-16 | 17 | 1/2 | AC | 73 | No regrowth | 0 | R | ||||||
| Docetaxel | 19 | 1 | 0 | No | |||||||||
| HBCx-17 | 12 | 0/3 | AC | 100 | No regrowth | 100 | High R | ||||||
| Docetaxel | 42 | 1.2 | 0 | No | |||||||||
Abbreviation: AC, Adriamycin-cyclophosphamide combination.
↵* Time in days required to double the tumor size, during the exponential phase of growth.
↵† TGI (tumor growth inhibition) is the optimal ratio between the mean tumor volume in the treated group and that in the control group × 100, at the same time.
↵‡ T/C growth delay index is the ratio between the survival of treated mice and the survival of control mice. This index cannot be calculated in case of complete response.
↵§ Four categories of HBCx responders (R) were defined as detailed in Materials and Methods: (a) high R, (b) responders (R), (c) Low R; and (d) the nonresponders (Not in the tables).